论文部分内容阅读
钙离子依赖型凝集素样受体2(calcium-dependent lectin-like receptor 2,CLEC-2)是近年发现的血小板表面受体,相对分子质量(Mr)约32 000,是一种Ⅱ型跨膜受体。蛇毒蛋白Rhodocytin和唾液酸样糖蛋白Podoplanin是目前被分别鉴定出的CLEC-2的外源性和内源性配体。配体与受体相互作用后,通过Src及Syk依赖的酪氨酸激酶途径活化下游分子,最终激活PLCγ2,产生第二信使的生理效应,引起血小板活化聚集。研究表明CLEC-2与配体的相互作用和血栓性疾病、肿瘤转移和进展以及血小板捕获HIV-1并呈递给靶细胞等过程密切相关。因此,阻断两者相互作用可能成为治疗上述疾病的新靶点。
Calcium-dependent lectin-like receptor 2 (CLEC-2) is a recently discovered platelet surface receptor with a relative molecular mass (Mr) of about 32,000 and is a Type II transmembrane Receptor. The snake venom proteins Rhodocytin and the sialic acid-like glycoprotein Podoplanin are the exogenous and endogenous ligands of CLEC-2, respectively identified to date. Ligand and receptor interaction, through Src and Syk-dependent tyrosine kinase pathway activation of downstream molecules, the final activation of PLCγ2, resulting in the second messenger of the physiological effects, causing platelet activation and aggregation. Studies have shown that the interaction of CLEC-2 with ligand and thrombotic diseases, tumor metastasis and progression, as well as platelet capture HIV-1 and presented to target cells and other processes are closely related. Therefore, blocking the interaction between the two may become a new target for the treatment of these diseases.